Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160369 | 1.00 | DPP4 (0.40) | DPP4KDM4ERAD52CXCR4CXCL12 | |
| SCHEMBL2751529 | 0.98 | SMN1; SMN2 (0.39) | DPP4KDM4ERAD52CXCR4CXCL12 | |
| SCHEMBL6977767 | 0.93 | — | — | |
| Alcohol SCHEMBL29090208 | 0.90 | DPP4 (0.39) | DPP4KDM4ERAD52CXCR4CXCL12 | |
| SCHEMBL1190555 | 0.88 | — | — | |
| SCHEMBL5831087 | 0.88 | JAK1 (0.39) | DPP4SMN1; SMN2DPP8DPP9ALDH1A1 | |
| SCHEMBL21089261 | 0.82 | JAK1 (0.36) | DPP4ALDH1A1HSD17B10 | |
| SCHEMBL9452822 | 0.80 | CXCR4 (0.34) | DPP4KDM4ERAD52CXCR4CXCL12 | |
| SCHEMBL7522442 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL6050954 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119782-A1 | METHOD FOR THE MANUFACTURE OF NEW AMINE | EVONIK OPERATIONS GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-114591200-B | Preparation method of dicyanoethyl tertiary amine | 万华化学集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-114890913-B | Method for preparing dicyanoethyl cyclohexylamine | 万华化学集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-114890913-A | Method for preparing dicyanoethyl cyclohexylamine | 万华化学集团股份有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114591200-A | Preparation method of dicyanoethyl tertiary amine | 万华化学集团股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20090048466-A1 | PROCESS FOR PREPARING AMINES BY CONDITIONING THE CATALYST WITH AMMONIA | EVONIK DEGUSSA GMBH (DE) | 2009-02-19 | — | — | US | claimed |
| EP-1984319-A1 | PROCESS FOR PREPARING AMINES BY CONDITIONING THE CATALYST WITH AMMONIA | Evonik Degussa GmbH (DE) | 2008-10-29 | — | — | EP | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-4042642-A | 1,3-BIS(MORPHOLINOTHIO)-IMIDAZOLIDINONE | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-08-16 | — | — | US | claimed |
| US-3996505-A | Capacitor with liquid polybutene dielectric | MCGRAW-EDISON COMPANY (US) | 1976-12-07 | — | — | US | claimed |
| US-3960857-A | Urea additives for sulfur vulcanizable polymers | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1976-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | DPP4 2080/4885KDM4E 4690/4885RAD52 2288/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | DPP4 454/4885KDM4E 4283/4885RAD52 3188/4885 |
| US-20090048466-A1 | PROCESS FOR PREPARING AMINES BY CONDITIONING THE CATALYST WITH AMMONIA | PNMT, HNMT, NAAA | DPP4 4381/4885KDM4E 1228/4885RAD52 2894/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | DPP4 2080/4885KDM4E 4690/4885RAD52 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.